Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer

Taher A. Al-Tweigeri, Dahish S. Ajarim, Adher A. Alsayed, Mohamed M. Rahal, Mohamed O. Alshabanah, Asma M. Tulbah, Osama A. Al-Malik, Doha M. Fatani, Gamal A. El-Husseiny, Naser Elkum, Adnan A. Ezzat

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2-T4, N0-N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%. Clinical complete response was seen in 44%, and clinical partial response was seen in 56%. Breast conserving surgery was performed in 44%, and MRM in 56%. pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82%, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.

Original languageEnglish
Pages (from-to)571-577
Number of pages7
JournalMedical Oncology
Volume27
Issue number3
DOIs
Publication statusPublished - Sep 2010
Externally publishedYes

Fingerprint

docetaxel
Axilla
Doxorubicin
Cisplatin
Breast Neoplasms
Breast
Survival
Segmental Mastectomy
Tamoxifen
Radiotherapy
Staining and Labeling
Safety
Drug Therapy

Keywords

  • Anthracycline
  • Cisplatin/docetaxel
  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Pathologic complete response

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Al-Tweigeri, T. A., Ajarim, D. S., Alsayed, A. A., Rahal, M. M., Alshabanah, M. O., Tulbah, A. M., ... Ezzat, A. A. (2010). Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Medical Oncology, 27(3), 571-577. https://doi.org/10.1007/s12032-009-9251-7

Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. / Al-Tweigeri, Taher A.; Ajarim, Dahish S.; Alsayed, Adher A.; Rahal, Mohamed M.; Alshabanah, Mohamed O.; Tulbah, Asma M.; Al-Malik, Osama A.; Fatani, Doha M.; El-Husseiny, Gamal A.; Elkum, Naser; Ezzat, Adnan A.

In: Medical Oncology, Vol. 27, No. 3, 09.2010, p. 571-577.

Research output: Contribution to journalArticle

Al-Tweigeri, TA, Ajarim, DS, Alsayed, AA, Rahal, MM, Alshabanah, MO, Tulbah, AM, Al-Malik, OA, Fatani, DM, El-Husseiny, GA, Elkum, N & Ezzat, AA 2010, 'Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer', Medical Oncology, vol. 27, no. 3, pp. 571-577. https://doi.org/10.1007/s12032-009-9251-7
Al-Tweigeri, Taher A. ; Ajarim, Dahish S. ; Alsayed, Adher A. ; Rahal, Mohamed M. ; Alshabanah, Mohamed O. ; Tulbah, Asma M. ; Al-Malik, Osama A. ; Fatani, Doha M. ; El-Husseiny, Gamal A. ; Elkum, Naser ; Ezzat, Adnan A. / Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. In: Medical Oncology. 2010 ; Vol. 27, No. 3. pp. 571-577.
@article{9f0deca93efa4acd90cfe8ab73c20cb0,
title = "Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer",
abstract = "The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2-T4, N0-N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68{\%}, median tumor size: 6.0 cm (4-10), Stage IIB: 32{\%} and IIIA/IIIB: 68{\%}, both ER/PR positive: 53{\%}, Her2/neu (3+) by IHC staining: 29{\%}. Clinical complete response was seen in 44{\%}, and clinical partial response was seen in 56{\%}. Breast conserving surgery was performed in 44{\%}, and MRM in 56{\%}. pCR in the breast was 30.5{\%}, in axilla was 37{\%}, and pCR in both breast and axilla was 24{\%}. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82{\%}, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100{\%}, respectively, while 14 patients relapsed of which 46{\%} were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.",
keywords = "Anthracycline, Cisplatin/docetaxel, Locally advanced breast cancer, Neoadjuvant chemotherapy, Pathologic complete response",
author = "Al-Tweigeri, {Taher A.} and Ajarim, {Dahish S.} and Alsayed, {Adher A.} and Rahal, {Mohamed M.} and Alshabanah, {Mohamed O.} and Tulbah, {Asma M.} and Al-Malik, {Osama A.} and Fatani, {Doha M.} and El-Husseiny, {Gamal A.} and Naser Elkum and Ezzat, {Adnan A.}",
year = "2010",
month = "9",
doi = "10.1007/s12032-009-9251-7",
language = "English",
volume = "27",
pages = "571--577",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer

AU - Al-Tweigeri, Taher A.

AU - Ajarim, Dahish S.

AU - Alsayed, Adher A.

AU - Rahal, Mohamed M.

AU - Alshabanah, Mohamed O.

AU - Tulbah, Asma M.

AU - Al-Malik, Osama A.

AU - Fatani, Doha M.

AU - El-Husseiny, Gamal A.

AU - Elkum, Naser

AU - Ezzat, Adnan A.

PY - 2010/9

Y1 - 2010/9

N2 - The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2-T4, N0-N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%. Clinical complete response was seen in 44%, and clinical partial response was seen in 56%. Breast conserving surgery was performed in 44%, and MRM in 56%. pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82%, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.

AB - The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2-T4, N0-N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%. Clinical complete response was seen in 44%, and clinical partial response was seen in 56%. Breast conserving surgery was performed in 44%, and MRM in 56%. pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82%, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.

KW - Anthracycline

KW - Cisplatin/docetaxel

KW - Locally advanced breast cancer

KW - Neoadjuvant chemotherapy

KW - Pathologic complete response

UR - http://www.scopus.com/inward/record.url?scp=77956899986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956899986&partnerID=8YFLogxK

U2 - 10.1007/s12032-009-9251-7

DO - 10.1007/s12032-009-9251-7

M3 - Article

C2 - 19526202

AN - SCOPUS:77956899986

VL - 27

SP - 571

EP - 577

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

ER -